Rituximab combined with Daratumumab（Anti-CD38 Monoclonal Antibody）
IIT2024069
Phase 2 small_molecule active
Quick answer
Rituximab combined with Daratumumab（Anti-CD38 Monoclonal Antibody） for Immune Thrombocytopenia is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Immune Thrombocytopenia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active